- Home
- MDGL vs RYTM Comparison
MDGL vs RYTM Comparison
Compare MDGL & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- RYTM
- Stock Information
- Founded
- MDGL 2011
- RYTM 2008
- Country
- MDGL United States
- RYTM United States
- Employees
- MDGL N/A
- RYTM N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- RYTM Health Care
- Exchange
- MDGL Nasdaq
- RYTM Nasdaq
- Market Cap
- MDGL 6.1B
- RYTM 5.9B
- IPO Year
- MDGL N/A
- RYTM 2017
- Fundamental
- Price
- MDGL $302.17
- RYTM $88.30
- Analyst Decision
- MDGL Strong Buy
- RYTM Strong Buy
- Analyst Count
- MDGL 9
- RYTM 13
- Target Price
- MDGL $420.63
- RYTM $89.77
- AVG Volume (30 Days)
- MDGL 371.3K
- RYTM 934.8K
- Earning Date
- MDGL 08-05-2025
- RYTM 08-05-2025
- Dividend Yield
- MDGL N/A
- RYTM N/A
- EPS Growth
- MDGL N/A
- RYTM N/A
- EPS
- MDGL N/A
- RYTM N/A
- Revenue
- MDGL $317,383,000.00
- RYTM $136,863,000.00
- Revenue This Year
- MDGL $286.67
- RYTM $37.86
- Revenue Next Year
- MDGL $67.98
- RYTM $72.72
- P/E Ratio
- MDGL N/A
- RYTM N/A
- Revenue Growth
- MDGL N/A
- RYTM 48.88
- 52 Week Low
- MDGL $200.63
- RYTM $40.61
- 52 Week High
- MDGL $377.46
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- MDGL 48.85
- RYTM 67.87
- Support Level
- MDGL $286.44
- RYTM $83.98
- Resistance Level
- MDGL $312.05
- RYTM $87.09
- Average True Range (ATR)
- MDGL 14.84
- RYTM 2.44
- MACD
- MDGL -3.14
- RYTM -0.91
- Stochastic Oscillator
- MDGL 22.01
- RYTM 52.97
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.